BHCM
BBOT

Brevan Howard Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Brevan Howard Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Buy
+14,248
New +$153K ﹤0.01% 1985

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brevan Howard Capital Management's BBOT Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in BridgeBio Oncology (BBOT) in Q1 2026: 14,248 shares worth $128K. The stake represents ﹤0.01% of the portfolio and ranks #1985 among its holdings.

67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Brevan Howard Capital Management held 14,248 shares of BridgeBio Oncology worth $128K as of Q1 2026.
  • BridgeBio Oncology was a new Brevan Howard Capital Management position in Q1 2026.
  • BridgeBio Oncology made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1985 holding.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.